Biomarker Testing and Guideline-Recommended Care in mNSCLC

Mark Socinski, MD, introduces a panel of medical experts as they kick off a discussion surrounding biomarker testing and guideline recommendations in the metastatic non-small cell lung cancer treatment landscape.

Now Viewing

EP: 1.Biomarker Testing and Guideline-Recommended Care in mNSCLC

EP: 2.Strategies to Increase Biomarker Testing Rates

EP: 3.Limitations on Optimal Biomarker Testing Rates

EP: 4.Impact of Biomarker Testing on Treatment Selection and Outcomes

EP: 5.Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

EP: 6.NCCN Recommendations by PD-L1 Expression Level

EP: 7.Limitations of NCCN PD-L1 Expression Recommendations

EP: 8.Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

EP: 9.Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

EP: 10.Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

EP: 11.Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection

EP: 12.Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches

EP: 13.Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

Video content above is prompted by the following:

What are the current NCCN guideline recommendations regarding molecular/genetic testing (NGS, etc.) for newly diagnosed mNSCLC patients?
Do the NCCN guideline recommendations for molecular/genetic testing and biomarker evaluation differ between squamous and non-squamous non-small cell lung cancer? If so, how, and why?
What is the rationale and clinical utility of comprehensive biomarker testing in this setting?